GlycoMimetics to Report First Quarter Financial Results on May 1, 2020
April 24 2020 - 09:00AM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will
host a conference call and webcast to report its first quarter
financial results on Friday, May 1, 2020, at 8:30 a.m. ET.
The dial-in number for the conference call is (844) 413-7154 for
domestic participants and (216) 562-0466 for international
participants, with participant code 4567397. A webcast replay will
be available via the “Investors” tab on the GlycoMimetics website
for 30 days following the call. A dial-in phone replay will be
available for 24 hours after the close of the call by dialing (855)
859-2056 for domestic participants and (404) 537-3406 for
international participants, participant code 4567397.
We encourage speakers and participants to connect early to
ensure that all callers are able to connect. Perhaps, include
language in earnings announcement and release to remind all
speakers/participants to dial in 15 minutes prior to the call start
time. Also, any callers who would like to ask questions, to queue
early in the call.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on the discovery and development of novel glycomimetic drugs to
address unmet medical needs resulting from diseases in which
carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned
drug candidate, uproleselan, an E-selectin antagonist, was
evaluated in a Phase 1/2 clinical trial as a potential treatment
for Acute Myeloid Leukemia and is being evaluated across a range of
patient populations including a Company-sponsored Phase 3 trial in
relapsed/refractory AML. GlycoMimetics has also completed a Phase 1
clinical trial with another wholly-owned drug candidate, GMI-1359,
a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn
more at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company’s strategy and the clinical development and potential
benefits and impact of its drug candidates. These forward-looking
statements include those relating to the planned clinical
development of the Company’s product candidates, including
expectations with regard to the enrollment of patients in its
ongoing Phase 3 clinical trial, and its other plans for its current
cash resources. Actual results may differ materially from those in
these forward-looking statements. For a further description of the
risks associated with these statements, as well as other risks
facing GlycoMimetics, please see the risk factors described in the
Company’s annual report on Form 10-K filed with the U.S. Securities
and Exchange Commission (SEC) on February 28, 2020, and other
filings GlycoMimetics makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this
release, and GlycoMimetics undertakes no obligation to update or
revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200424005292/en/
Investor Contact: Shari Annes Phone: 650-888-0902 Email:
sannes@annesassociates.com
Media Contact: Jamie Lacey-Moreira Phone: 410-299-3310 Email:
jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Feb 2024 to Mar 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2023 to Mar 2024